Gabapentin Capsule
Product Images NDC 71335-2478

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Gabapentincapsules 01)

A formula panel showing the equation to calculate creatinine clearance (CLCr). It includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients. This is typically used in clinical contexts.*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure of Gabapentin displayed as a cyclohexane ring with two side chains: an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph illustrating the mean pain score over eight weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows the mean pain score from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, showing decreasing pain scores for Gabapentin while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

A line graph showing mean pain score over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks and the y-axis shows mean pain score from 0 to 10. It includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses in two studies. Study 1 shows 12% responders for placebo and 29% for Gabapentin 3600 mg. Study 2 shows 14% responders for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg. Statistical significance is indicated with p-values < 0.01 and < 0.001.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot comparing percentage differences by daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis shows daily doses from 600 to 1800 mg; the y-axis shows percentage difference from 2% to 22%. Each study is represented by different markers and shows data points at various doses with annotated letters.*

FDA Label Image

Label (Lbl713352478)

Label for Gabapentin Capsules USP 400 mg showing NDC 71335-2478-1. The package contains 20 capsules, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Zhejiang Yontai Pharmaceuticals Co., Ltd. Storage instructions and safety warnings about child-resistant containers and dizziness are included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.